Announcements Trials
Browse Landscape

Status

Completed 231Recruiting 131Unknown 85Active not recruiting 60Terminated 53Withdrawn 20Not yet recruiting 19Enrolling by invitation 6No longer available 4Approved for marketing 2Suspended 1Available 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Expanded_access 4

Sponsor

Cancer Type

Gastrointestinal 27Other hematologic neoplasm 25CNS 25Genitourinary 24Plasma cell 22Lymphoid 22Thoracic 20Dermatologic 20Sarcoma 18Breast 12Myeloid 10Other solid neoplasm 9Tumor-Agnostic 8Endocrine 8NET 4Other neoplasm 3Head & Neck 3Gynecologic 3Classical hematology 1

Conditions

Neuroendocrine Tumors 4Carcinoma, Medullary 1Carcinoid Tumor 1

Interventions

Ga(III)-DOTATOC 2surufatinib 1Gallium-68 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
No longer available × NET × Clear all
NCT04814732 2024-04-12

Expanded Access Program of Surufatinib

Hutchmed

No longer available
EndocrineNET

Neuroendocrine Tumors

NCT02174679 2020-07-27

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Jonsson Comprehensive Cancer Center

No longer available
EndocrineNET

Carcinoma, Medullary, Neuroendocrine Tumors

NCT02375464 2016-11-08

Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

Northwell Health

No longer available
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT02358018 2016-11-02

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Memorial Sloan Kettering Cancer Center

No longer available
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡